Cellectar Biosciences, Inc.
Cellectar Biosciences is dedicated to developing targeted cancer treatments using its innovative phospholipid ether (PLE) platform technology. The company focuses on designing and advancing drug candidates rapidly, with a pipeline that includes proprietary products like Iopofosine, and collaborates strategically to improve therapeutic outcomes for cancer patients worldwide.
Industries
Nr. of Employees
small (1-50)
Cellectar Biosciences, Inc.
Madison, Wisconsin, United States, North America
Products
Iopofosine (CLR 131)
A small-molecule phospholipid ether-based radioconjugate labeled with iodine-131 designed for selective tumor cell uptake and intracellular radiation delivery; evaluated in multiple clinical studies and indications including Waldenstrom’s macroglobulinemia, multiple myeloma, and high-grade glioma.
CLR 1900 series
Internally developed series of phospholipid ether-conjugated small-molecule cytotoxics that target cell division pathways; currently in early preclinical development for solid tumors.
CLR 12120 series (alpha-emitting radioconjugates)
Alpha-emitting phospholipid ether radioconjugate program using actinium-225 payloads under development for treatment of refractory solid tumors.
CLR 125 (candidate for triple-negative breast cancer)
Product candidate advanced toward a Phase 1b clinical protocol submission to regulatory authorities for treatment of triple-negative breast cancer.
Iopofosine (CLR 131)
A small-molecule phospholipid ether-based radioconjugate labeled with iodine-131 designed for selective tumor cell uptake and intracellular radiation delivery; evaluated in multiple clinical studies and indications including Waldenstrom’s macroglobulinemia, multiple myeloma, and high-grade glioma.
CLR 1900 series
Internally developed series of phospholipid ether-conjugated small-molecule cytotoxics that target cell division pathways; currently in early preclinical development for solid tumors.
CLR 12120 series (alpha-emitting radioconjugates)
Alpha-emitting phospholipid ether radioconjugate program using actinium-225 payloads under development for treatment of refractory solid tumors.
CLR 125 (candidate for triple-negative breast cancer)
Product candidate advanced toward a Phase 1b clinical protocol submission to regulatory authorities for treatment of triple-negative breast cancer.
Services
Clinical development and trial execution (oncology)
Design and conduct of oncology trials including dose-finding, Phase 1, and pivotal expansion studies; management of trial sites and patient enrollment.
Co-development and strategic partnership collaborations
Joint development arrangements and licensing/co-development options to combine delivery platform expertise with external linkers, payloads, or commercialization capabilities.
Academic research proposal intake and collaboration support
Process and documentation support for academic groups seeking to collaborate on preclinical research using the delivery platform.
Expanded access program administration
Policies and procedures to manage requests for expanded access to investigational therapeutics in clinical development.
Clinical development and trial execution (oncology)
Design and conduct of oncology trials including dose-finding, Phase 1, and pivotal expansion studies; management of trial sites and patient enrollment.
Co-development and strategic partnership collaborations
Joint development arrangements and licensing/co-development options to combine delivery platform expertise with external linkers, payloads, or commercialization capabilities.
Academic research proposal intake and collaboration support
Process and documentation support for academic groups seeking to collaborate on preclinical research using the delivery platform.
Expanded access program administration
Policies and procedures to manage requests for expanded access to investigational therapeutics in clinical development.
Expertise Areas
- Targeted drug delivery
- Radiopharmaceutical development
- Conjugation and linker chemistry
- Preclinical pharmacology and animal models
Key Technologies
- Phospholipid ether-based targeting platform
- Radiolabeled small-molecule therapeutics
- Alpha-emitter therapeutics
- Linker-to-warhead conjugation chemistry